ScripInDex Pharmaceuticals Holding AB 's chances of survival looked slim after the late-stage failure of lead asset cobitolimod for ulcerative colitis but it seems as though the Swedish biotech will find s
ScripIt looks like the writing is on the wall for InDex Pharmaceuticals Holding AB after the Swedish company announced that it would discontinue the late-stage program of lead asset cobitolimod for ulcer
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Daewoong, HanAll Co-Invest In Vinc
ScripAstraZeneca PLC has discontinued its anti-IL-23 monoclonal antibody, brazikumab, for inflammatory bowel diseases (IBD) as the market and pipeline become increasingly crowded and following unavoidable